Minute Insight: Angle’s Parsortix Gets FDA Approval, Marking New Era For Liquid Biopsy
The FDA has approved Angle’s Parsortix circulating tumor cell cancer capturing system, which the company believes will be a paradigm shift for liquid biopsy in the US and heighten competition in the oncology diagnostics space.
You may also be interested in...
Epic Sciences spoke to Medtech Insight to discuss the development of its DefineMBC test for metastatic breast cancer.
In this first edition of Report Digest, UK-based reporter Barnaby Pickering discusses the liquid biopsy for oncology market with analyst Phil Greenfield. The two discuss the main market drivers and what experts think will occur in the sector in future years.
Following a successful fundraise, Angle is poised to further commercialize its proprietary cell-catching technology for cancer diagnosis